AlloVir Stockholders Approve Key Amendment and Merger
AlloVir stockholders approved an amendment to the 2020 Stock Option and Grant Plan, increasing shares for future issuance and extending the plan’s term. This amendment, along with the merger with Kalaris, aims to enhance AlloVir’s capital base and market position, despite associated risks. AlloVir focuses on developing cell therapies for viral infections, particularly for patients with weakened immune systems. Current market cap is $29.22M, with a YTD price performance of -1.76% and a consensus rating of Buy.
AlloVir ( (ALVR) ) has issued an update.
On March 12, 2025, AlloVir held a special meeting where stockholders approved an amendment to the 2020 Stock Option and Grant Plan, increasing the number of shares available for future issuance and extending the plan’s term. The approval of this amendment and the merger with Kalaris, which involves a change of control and issuance of new shares, is expected to impact AlloVir’s operations by expanding its capital base and potentially enhancing its market position, although there are inherent risks and uncertainties associated with the merger.
More about AlloVir
AlloVir is a company operating in the biotechnology industry, focusing on the development of cell therapies to treat viral infections. The company’s primary products are designed to address viral diseases in patients with weakened immune systems, with a market focus on providing innovative solutions for unmet medical needs in this area.
YTD Price Performance: -1.76%
Average Trading Volume: 23,011
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $29.22M
See more data about ALVR stock on TipRanks’ Stock Analysis page.
Trending Articles:
- Target (NYSE:TGT) Puts More Into its Grocery Supply Chain
- The Ford (NYSE:F) Heritage Fleet Rolls Out
- Intel (NASDAQ:INTC) Rolls out Panther Lake System-on-a-Chip Units
Questions or Comments about the article? Write to editor@tipranks.com
